Nuvectis Pharma, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & Equivalents | $31.6M | $18.5M | $19.1M | $20.0M | $5.7M |
| Accounts Receivable | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Total Current Assets | $31.7M | $18.6M | $19.2M | $20.4M | $5.8M |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — |
| Total Assets | $31.7M | $18.6M | $19.2M | $20.4M | $6.7M |
| Liabilities | |||||
| Accounts Payable | $6.3M | $2.5M | $2.8M | $2.9M | $1.1M |
| Total Current Liabilities | $13.3M | $8.9M | $7.0M | $6.2M | $2.4M |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $13.3M | $8.9M | $7.0M | $6.2M | $2.4M |
| Stockholders' Equity | |||||
| Retained Earnings | $-99.7M | $-73.2M | $-54.2M | $-32.0M | $-12.9M |
| Total Stockholders' Equity | $18.4M | $9.7M | $12.2M | $14.2M | $-11.0M |